Recurrent chromosomal aberrations in INK4a/ARF defective primary lymphomas predict drug responses in...
Recurrent chromosomal aberrations in INK4a/ARF defective primary lymphomas predict drug responses in vivo
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Predicting responsiveness to anticancer therapy based on molecular findings at diagnosis is important to optimize treatment decisions. Although clinical outcome correlates with distinct mutations in some cancer entities, treatment responses within these lesion-stratified subgroups still remain heterogeneous, underscoring the need for additional pro...
Alternative Titles
Full title
Recurrent chromosomal aberrations in INK4a/ARF defective primary lymphomas predict drug responses in vivo
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_67939326
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_67939326
Other Identifiers
ISSN
0950-9232
E-ISSN
1476-5594
DOI
10.1038/sj.onc.1208600
